文献速递肾小球疾病

膜性肾病的摩尔定律

Moore's law for membranous nephropathy.
PubMed 文献 · Kidney Int · 2020-01-01

自M型磷脂酶A2受体1(PLA2R1)报道以来,膜性肾病靶抗原的发现加速,技术进展使该领域呈现类似摩尔定律的倍增趋势。本期Kidney International中Sethi等报道semaphorin-3B为新型靶抗原,定义了儿童起病的一种膜性肾病类型,未来预期发现更多抗原。

要点

  • 膜性肾病靶抗原发现速度加快,呈类似摩尔定律的倍增趋势。
  • semaphorin-3B被报道为新型靶抗原,定义儿童起病的膜性肾病类型。
  • 未来预期可发现更多膜性肾病靶抗原。

核心结论

  • 膜性肾病靶抗原发现加速,呈现类似摩尔定律的倍增趋势,未来预期发现更多抗原。

研究设计与样本

  • 本文为针对Sethi等在Kidney International发表研究的评论文章。

主要发现

  • Sethi等描述semaphorin-3B为新型靶抗原,定义儿童起病的膜性肾病类型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The identification of target antigens in membranous nephropathy has accelerated since the report of M-type phospholipase A2 receptor 1 (PLA2R1). One could say that technological advances have allowed for the demonstration of Moore's law (a doubling every 2 years in the number of transistors that can be fit onto a computer chip) in the field of membranous nephropathy, and that even more antigens can be expected in the near future. In this issue of Kidney International, Sethi et al. describe semaphorin-3B as a novel target antigen, defining a type of membranous nephropathy with onset in the pediatric population.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hayashi N, Beck LH. Moore's law for membranous nephropathy. Kidney Int. 2020. PMID: 33126969. doi:10.1016/j.kint.2020.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。